TickerTalks
Browse all tickers →
TickerTalks›$DFTX
DFDFTX

Definium Therapeutics, Inc.

$DFTX·$4.3B·Biotechnology·Healthcare
$32.97+2.7%YTD+153.8%1Y+150.5%
Price updated 5h ago·X counts updated 8d ago
DFDFTX
$DFTXDefinium Therapeutics, Inc.
$32.97+2.71%80 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $DFTX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

80X posts · last 7 days
Oct 2Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $DFTX's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data15 posts analyzed · as of 2026-09-15

FDA Breakthrough Therapy designation for DT120 in Major Depressive Disorder is the dominant catalyst, with posters flagging a pro-psychedelic FDA leadership shift and a second GAD Phase 3 readout due this month. Hedge-fund ownership counts and 'data is undeniable' framing reinforce the excitement.

Read what X is saying about $DFTX

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $DFTX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventAcceleratingAI verdict · as of 2026-10-03

The move is getting stronger, with heavier trading behind it.

FDA Breakthrough Therapy for DT120 in MDD — Definium is up 177% YTD on a specific regulatory inflection.

Definium Therapeutics is a clinical-stage CNS biopharma whose lead asset DT120 just received FDA Breakthrough Therapy designation for Major Depressive Disorder. The 2026 story has gone from 'psychedelic-adjacent speculation' to 'regulatory-pathway validated' in a single quarter.

  • The P&L is pre-revenue: zero quarterly revenue with EPS of -$0.71 and trailing EPS prints missing Street estimates by 166% and 51% — this is a biotech funded through pivotal trials, with the stock trading on regulatory and clinical milestones rather than quarterly numbers.
  • The specific catalyst stack is unusually clean: the FDA Breakthrough Therapy designation plus a pro-psychedelic FDA leadership shift plus a second GAD Phase 3 readout due this month — three convergent signals that bear directly on the regulatory and commercial pathway.

At 69% of its 52-week range and 38% above the 200-day going into Nov 5 earnings, this is a confirmed-breakout biotech setup. The second GAD Phase 3 readout being positive plus NDA pathway commentary is the trigger for continuation; a negative GAD readout or any safety-signal escalation is the invalidation.

Agrees with X sentimentThe FDA Breakthrough Therapy framing is a specific grounded datapoint. The hedge-fund-ownership and 'data is undeniable' framings are promotional-tone, but the regulatory event is real and material.

What to watch: Nov 5 Q3 earnings and the second GAD Phase 3 readout — Phase 3 outcome, DT120 NDA pathway commentary, cash runway, and any additional pipeline detail. Positive GAD data plus NDA pathway is the trigger; negative readout is the invalidation.

On the calendar: 2026-11-05 — Q3 earnings

event ahead 30dbreakthrough therapy

Read the AI verdict on $DFTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing psychedelic-based therapies (synthetic LSD derivative MM120) for anxiety and ADHD.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $DFTX.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $DFTX

Neutral — Clinical-stage biotech developing psychedelic-based therapies (synthetic LSD derivative MM120) for anxiety and ADHD.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-10.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-60.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-102%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-1.44$-0.54-166.2%
Q1 2026May 7, 2026$-0.71$-0.47-51.1%
Q4 2025Feb 26, 2026$-0.51$-0.48-5.4%
Q3 2025Nov 6, 2025$-0.78$-0.52-50.0%
Next earningsThu, Nov 5·consensus EPS $-0.56

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.71$-42.6M
Q4 FY25$0———$-0.51$-41.9M
Q3 FY25$0———$-0.78$-29.6M
Q2 FY25$0———$-0.50$-29.6M

Forward consensus

5-year forecast · up to 13 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$3.19-$3.71 – -$2.380
FY27$29.3M$6.8M – $136.7M-$2.05-$2.57 – -$1.6210
FY28$270.8M$36.3M – $1.4B-$0.86-$2.24 – $4.7913
FY29$644.8M$149.1M – $3.0B$1.10$0.00 – $6.3411
FY30$1.2B$268.4M – $5.4B$3.81$0.00 – $21.956

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.55%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-18.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+12.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 127.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.195-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 25Mark SullivanChief Legal Officer14.1K sh$514KSellSep 25Daniel KarlinChief Medical Officer10.9K sh$397KSellSep 25Robert BarrowCEO31.6K sh$1.2MSellSep 25Matthew T. WileyChief Commercial Officer3.1K sh$113KSellSep 25Brandi RobertsCFO3.4K sh$123KSellSep 3Robert BarrowCEO19.0K sh$722KSellJun 25Mark SullivanChief Legal Officer13.0K sh$586KSellJun 25Matthew T. WileyChief Commercial Officer2.9K sh$129KSellJun 25Brandi RobertsCFO3.0K sh$136KSellJun 25Robert BarrowCEO29.2K sh$1.3M
1–10 of 11
+ 24 other (22 awards · 2 exempts) in window

See when $DFTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 148-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Definium Therapeutics (DFTX) announced positive topline results from its Phase 3 Panorama study of DT120 ODT (oral dissolving tablet) for generalized anxiety disorder (GAD), with the study meeting its primary endpoint. This is a pivotal milestone for the company's lead clinical asset and provides the evidence package needed to support an NDA submission to the FDA. Positive Phase 3 results in GAD substantially de-risk the regulatory pathway and support a potential path to commercialization for DT120 ODT. This represents a significant binary catalytic event for a clinical-stage biotech.

8-KPress release / Reg FDAug 128-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Definium Therapeutics, Inc. (DFTX), a British Columbia-incorporated clinical-stage company listed on Nasdaq, announced on August 12, 2026, positive topline data from its Phase 3 Voyage study of DT120 ODT for the treatment of generalized anxiety disorder (GAD). The company simultaneously posted a detailed data presentation to its website and filed the press release as Exhibit 99.1 and the presentation as Exhibit 99.2. A successful Phase 3 readout in GAD is a significant clinical and regulatory milestone, as it could support a New Drug Application submission to the FDA. Generalized anxiety disorder is a large and underserved market, giving a positive Phase 3 result substantial commercial implications if the data hold up to regulatory scrutiny. CEO Robert Barrow signed the filing, and the positive trial outcome makes DFTX a name to watch for potential partnership or approval catalysts in the near term.

8-KMaterial agreementJun 248-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

Definium Therapeutics entered an underwriting agreement on June 23, 2026 for a public offering of 20,588,236 common shares at $34.00/share (prior close $36.18). The underwriter greenshoe of 3,088,235 shares was exercised in full on June 24, 2026. Gross proceeds including greenshoe are ~$805M; net proceeds ~$758M, earmarked for R&D, potential commercialization of DT120 ODT, and working capital. Material — a major capital raise at a ~6% discount to market; significant dilution for existing shareholders.

424B5Prospectus supplement (offering)Jun 24424B5
AI summary

Definium Therapeutics filed a 424B5 prospectus supplement on June 23, 2026 for an offering of 20,588,236 common shares at $34.00/share, with a 3,088,235-share overallotment option. Gross proceeds of ~$700M base ($805M with full greenshoe); underwriting discounts of ~$40.3M base ($46.3M with greenshoe). Bookrunners: J.P. Morgan, Jefferies, Leerink Partners, BofA Securities. Material dilution event — confirms pricing and terms of the large equity raise at a discount to market.

424B5Prospectus supplement (offering)Jun 22424B5
AI summary

Definium Therapeutics, Inc. filed a preliminary 424B5 prospectus supplement for a $500M public offering of common shares and pre-funded warrants (plus a $75M overallotment option), with shares last trading at $24.48 on June 18, 2026 and per-share pricing still to be determined. Bookrunners include J.P. Morgan, Jefferies, Leerink Partners, and BofA Securities. A large, immediately dilutive raise for an emerging growth therapeutics company, appearing concurrent with positive Phase 3 MDD data.

8-KPress release / Reg FDJun 228-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Definium Therapeutics, Inc. announced positive topline data on June 22, 2026 from its Phase 3 'Emerge' study of DT120 ODT (oral dissolving tablet) for the treatment of major depressive disorder, simultaneously posting a data presentation on its website. Specific efficacy metrics (primary endpoint results, p-values, effect size) are in the attached press release (Exhibit 99.1) and presentation (Exhibit 99.2). Positive Phase 3 MDD data is a highly material, potentially transformative clinical milestone signaling regulatory submission eligibility, concurrent with Definium's $500M equity raise.

8-KOfficer or director changeJun 128-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Definium Therapeutics, Inc. held its 2026 Annual General and Special Meeting on June 11, 2026. Shareholders approved an amendment to the 2025 Equity Incentive Plan adding 5,000,000 common shares for issuance; director elections and other standard proposals also passed. The 5M share plan expansion is the material disclosure — a meaningful dilution event for a small therapeutics company, reflecting typical early-stage equity compensation requirements.

+ 13 other (3 routine 8-Ks · 3 13Gs · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Definium Therapeutics Announces New Employee Inducement Grantsbusinesswire.com·6d agoDefinium Therapeutics Announces New Employee Inducement Grantsbusinesswire.com·21d agoDefinium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depressiondefenseworld.net·26d agoDefinium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depressionmarketbeat.com·26d agoDefinium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Studydefenseworld.net·29d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport